Status: Recruiting
Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.
Participants needed: 140
Trial details
Age: 21-75Biological sex: AllType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Jan 22, 2026Locations: 1
Eligibility criteria
No prior history of lung cancer [+11]
Pregnant or breastfeeding women [+3]